ClinicalTrials.gg
RecruitingNCT07021079NEUROVIB-ULLSUpdated May 26, 2026

Muscle Vibration as a Countermeasure Against Hypoactivity-induced

An interventional study of Focal muscle vibration and NO Focal muscle vibration in Vibration Therapy, Healthy Volunteer Study and Hypoactivity, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Sedentary Behavior with a site in France — 25 open to participants now, 27 under way, none of them phase 3. Sedentary Behavior · France.

Planned enrollment
28th of 39
42 · median 66
Started
2025
with 10 others
No phase
39 of 56
16 open now
Primary completion
2027-06
later than 20 of 26 live
Registered
43rd of 56
by date
Lead sponsor
8 of 56
Centre Hospitalier Universitaire de Saint Etienne

Among the 56 studies in Sedentary Behavior with a site in France, this one is the 28th largest by planned enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2025, is one of 39 with no phase, reaches primary completion later than 20 of the 26 other live ones, and was the 43rd registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

25 of the 56 studies in Sedentary Behavior with a site in France are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 19 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Sedentary Behavior with a site in France, or all of them as a file.
02

Study summary

Muscle deconditioning, characterized by a loss of muscle mass and strength, is a frequent consequence of prolonged lower limb unloading. Beyond muscle mass loss, reduced neural drive contributes significantly to strength decline, highlighting the need for interventions targeting neuromuscular function during immobilization. Focal muscle vibration (FMV) has shown promise in modulating neuromuscular excitability by activating muscle spindle afferents and inducing cortical adaptations. Chronic use of FMV has been associated with significant strength gains and improved neural command. This makes FMV an effective rehabilitation tool. Its simplicity and non-invasiveness further make it a practical countermeasure.

Read the detailed description

This study hypothesizes that a 10-day FMV protocol can induce neural adaptations to limit strength loss during unilateral lower limb suspension, offering a novel strategy against neuromuscular function decline.

03

Conditions studied

  • Vibration Therapy
  • Healthy Volunteer Study
  • Hypoactivity

Browse trials for

Keywords

  • hypoactivity
  • neuromuscular deconditionning
  • Vibration
04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women.
  • Aged 18 to 45 years.
  • (BMI) between 18,5 and 24,9 kg/m².
  • Engaging in at least 1.5 hours per week of physical activity (e.g., brisk walking, running, swimming, cycling).
  • Provided after receiving detailed information about the study.
  • Affiliated with or beneficiaries of a social security system

Exclusion criteria

Exclusion Criteria:

  • Chronic cardiovascular, neuromuscular, bone, metabolic, and/or inflammatory disorders.
  • Personal history and/or risk factors for thrombosis.
  • Use of antidepressant medications.
  • Use of neuroactive substances likely to alter corticospinal excitability (e.g., hypnotics, antiepileptics, psychotropics, muscle relaxants) during the study.
  • Recent bone or ligament trauma within the past 12 months.
  • Inability to perform the physical efforts required for the study.
  • Recent participation in a sporting competition or intense, unusual physical activity within the past month.
  • treatment within the past 3 months.
  • Any skin lesions at the planned vibrator application site.
  • Simultaneous participation in another interventional medical study.
  • Pregnant or breastfeeding women.
  • Individuals unable to understand the purpose and conditions of the study or unable to provide .
  • Individuals deprived of liberty or under guardianship
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Active comparator
    VIBRATION

    Participants will benefit a local vibration countermeasure program for the knee extensor muscles.

    Device: Focal muscle vibration

  • Sham comparator
    CONTROLE

    the control group WILL not receive this countermeasure.

    Device: NO Focal muscle vibration

Interventions

  • DeviceFocal muscle vibration

    focal muscle vibration sessions, using small and portable vibrator devices.

  • DeviceNO Focal muscle vibration

    The control group will not receive any intervention.

06

What researchers measure

Primary outcomes

  1. Isometric force measurement

    Maximal isometric force (% decrease) in knee extension of the immobilized leg will be evaluated

    Time frame: Day 1, 7, 14, 28, 33

Secondary outcomes

  1. Maximum voluntary force measurement

    Maximum voluntary force (Nm) in knee extension, assessed in isometric (for the immobilized leg and also for the contralateral leg), concentric (+60°/s and +180°/s) and eccentric (-60°/s) conditions.

    Time frame: Day 1, 7, 14, 28, 33

  2. Jumping performance measurement

    Jumping performance (height, in cm), assessed in vertical jump tests (Squat Jump and Counter Movement Jump).

    Time frame: Day 1, 7, 14, 28, 33

  3. Postural balance measurement

    Postural balance performance (displacement of center of pressure, in mm), assessed in a unipodal postural balance test performed on a strength platform

    Time frame: Day 1, 7, 14, 28, 33

  4. Neuromuscular fatigue measurement

    Neuromuscular fatigue (decrease in maximum voluntary force (in %), assessed during a fatigue protocol consisting of quadriceps muscle contractions at incremental force levels.

    Time frame: Day 1, 7, 14, 28, 33

  5. Force-velocity-endurance measurement

    Force-velocity-endurance profile, assessed during an effort performed on a cycloergometer at linearly decreasing power values.

    Time frame: Day 1, 7, 14, 28, 33

  6. Voluntary activation level evaluation

    Voluntary activation level (in %), determined by the force increment obtained following stimulation during a maximal voluntary isometric contraction.

    Time frame: Day 1, 7, 14, 28, 33

  7. Cortico-spinal excitability measurement

    Cortico-spinal excitability, assessed by electromyographic responses (motor evoked potentials, in mV) evoked by transcranial magnetic stimulation (TMS).

    Time frame: Day 1, 7, 14, 28, 33

  8. Spinal excitability evaluation

    Spinal excitability (i.e. spinal reflexes, in mV), assessed by recording EMG responses evoked by electrical stimulation of the lumbar vertebrae.

    Time frame: Day 1, 7,14 , 28, 33

  9. Cortical activation of sensorimotor areas measurement

    Cortical activation of sensorimotor areas, assessed by recording the electroencephalographic (EEG) signal during submaximal isometric contractions.

    Time frame: Day 1, 7, 14, 28, 33

  10. Muscle volume measurement

    Muscle volume will be assessed by ultrasound of the thigh muscles (in cm2).

    Time frame: Day 1, 7, 14, 28, 33

  11. Determination of plasma molecular markers of bone and muscle remodeling

    Assessment of blood factors of nerve (BDNF) and muscle remodeling (circulating steroids, insulin, GH, IGF-1, myostatin, activinA, follistatin).

    Time frame: Day 1, 7, 14, 28, 33

  12. Determination of plasma molecular markers of bone and muscle remodeling

    Evaluation of bone remodeling factors by bAP, CTx, P1NP and Trap5b assays

    Time frame: Day 1, 7, 14, 28, 33

  13. Plasma molecular markers of thrombotic risk evaluation

    Plasma molecular markers of thrombotic risk will be assessed by blood sampling followed by assay of HSP47 and D-dimer factors.

    Time frame: Day 1, 7, 14, 28, 33

07

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier Universitaire
    Saint-Etienne, 42055, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 23 months is above that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Jun 13, 2025
StartActual
Jun 16, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Aug 31, 2027
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021079
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jun 16, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 26, 2026

Study contacts

LEONARD FEASSON, PHD
Contact
leonard.feasson@chu-st-etienne.fr
(0)477120383 ext. +33
LEONARD FEASSON, PHD
principal investigator · CENTRE HOSPITALIER UNIVERSITAIRE SAINT-ETIENNE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion